INTRODUCTION
Cannabis- known botanically as Cannabis sativa occupies one of the most contested positions in contemporary legal discourse. Whether one approaches the question from the vantage of criminal law, public health regulation, or constitutional rights theory, the legal status of cannabis resists easy categorisation. It sits at the intersection of personal autonomy, state sovereignty, and international treaty obligations, generating a body of jurisprudence that is as sprawling as it is contradictory. This blog seeks to critically examine the regulatory architecture governing cannabis across key jurisdictions, with particular emphasis on permissibility thresholds, the distinction between medicinal and recreational use, and the judicial reasoning that has shaped and continues to reshape this evolving area of law.
THE INTERNATIONAL BASELINE: TREATY OBLIGATIONS AND THEIR LIMITS
Any comparative analysis of cannabis law must begin with the international framework. The Single Convention on Narcotic Drugs 1961[1] remains the foundational instrument, classifying cannabis as a Schedule I and Schedule IV substance the latter designation indicating substances deemed particularly liable to abuse and of limited therapeutic utility. State parties are obliged, under Article 36, to criminalise production, sale, and possession for non-medical purposes[2]. This obligation, however, has increasingly been strained by domestic reform movements, raising the doctrinal question of whether national legalisation schemes are compatible with treaty law or constitute a de facto breach, mitigated only by the absence of an enforcement mechanism.
The tension between international narcotics control and domestic liberalisation is not merely political it is a live question of public international law that courts have yet to definitively resolve.
The Convention on Psychotropic Substances 1971[3] and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 1988[4] further reinforce prohibitionist norms, yet none of these instruments has successfully restrained the trajectory of domestic reform a testament to the supremacy of national sovereignty in the realm of criminal law.
UNITED STATES: A PATCHWORK OF PERMISSIBILITY
The United States presents perhaps the most vivid illustration of legal fragmentation. At the federal level, cannabis remains a Schedule I controlled substance under the Controlled Substances Act 1970[5], placing it in the same category as heroin and rendering its manufacture, distribution, or possession a federal criminal offence. Yet, as of 2025, over twenty states have enacted comprehensive adult-use legalisation statutes, with a further dozen permitting medical use.
GONZALES V RAICH, 545 US 1 (2005)
The Supreme Court held, applying the Commerce Clause, that Congress retained authority to regulate purely intrastate cultivation of cannabis. The majority opinion, delivered by Stevens J, affirmed that the Controlled Substances Act validly applied even where a state had authorised medical cannabis effectively subordinating state permissibility schemes to federal prohibition.
Gonzales v Raich[6] remains the governing precedent at the federal level and illustrates the constitutional tension that pervades American cannabis law. The doctrine of federal supremacy, enshrined in the Supremacy Clause of Article VI, means that state-level legalisation creates a zone of legal risk for individuals and businesses operating within it they may be immune from state prosecution whilst remaining technically exposed to federal liability.
THRESHOLD QUANTITIES AND GRADED OFFENCES
In those states permitting adult recreational use California being the paradigm possession of up to twenty-eight grams (one ounce) is lawful for persons aged twenty-one and above under the Control, Regulate and Tax Adult Use of Marijuana Act 2016 (Proposition 64)[7]. Cultivation of up to six plants per household is similarly decriminalised. Possession above these thresholds, or any commercial activity absent a state licence, attracts criminal liability evidencing the legislature’s preference for a tiered, quantity-sensitive regulatory regime.
THE UNITED KINGDOM: FIRM PROHIBITION WITH MEDICAL EXCEPTION
The United Kingdom maintains a distinctly prohibitionist posture. Cannabis is classified as a Class B controlled drug under Schedule 2 of the Misuse of Drugs Act 1971[8], following its reclassification from Class C in 2009 by the then Home Secretary a decision that attracted significant criticism from the Advisory Council on the Misuse of Drugs, whose scientific recommendations were overridden on policy grounds[9].
Possession carries a maximum penalty of five years’ imprisonment and an unlimited fine; supply and production attract up to fourteen years sentences that reflect Parliament’s continued commitment to deterrence as the primary regulatory instrument. The reclassification decision was itself judicially examined in oblique terms in R (on the application of Bayer plc) v Secretary of State for Health[10], though the courts have generally declined to interfere with executive discretion in narcotics scheduling.
R V DEYEMI AND EDWARDS [2007] EWCA CRIM 2060
The Court of Appeal confirmed that possession of a controlled drug is a strict liability offence in respect of the fact of possession, though knowledge of the item’s-controlled nature remains required. This distinction has profound implications for cannabis-related prosecutions where defendants raise mistaken belief as to the substance’s identity.
A significant, albeit narrow, exception was carved out in 2018 when the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018[11] permitted specialist medical practitioners to prescribe cannabis-based medicinal products. This reform was catalysed by high-profile cases involving children with severe epilepsy, yet the clinical gatekeeping conditions remain stringent, and access continues to be characterised by advocates as inadequate[12].
The Netherlands exemplifies a particularly instructive paradox: cannabis retail is tolerated through the gedoogbeleid (tolerance policy) at the front-end of coffeeshops, yet cultivation and wholesale supply remain technically criminal a structural incoherence the Dutch legislature has struggled to resolve for decades[13]. Canada’s Cannabis Act 2018[14] represents the most comprehensive federal legalisation framework among major Western states, establishing a regulatory regime for production, distribution, sale, and possession, whilst preserving robust youth-protection provisions.
THE INDIAN CONTEXT: NDPS AND ITS PECULIARITIES
India’s Narcotic Drugs and Psychotropic Substances Act 1985[15] prohibits cannabis resin (charas) and cannabis flowers (ganja), yet conspicuously excludes leaves and seeds a carve-out that renders the traditional drink bhang technically lawful in several states. This legislative anomaly reflects the deep cultural embeddedness of certain cannabis uses, producing a regulatory regime that is simultaneously moralistic and selectively permissive. The Supreme Court in State of Punjab v Baldev Singh[16] addressed procedural safeguards under the NDPS Act, holding that non-compliance with mandatory search procedures under section 50 vitiates a conviction a judgment that has had significant practical consequences for enforcement.
CONCLUSION: TOWARDS A COHERENT LEGAL EPISTEMOLOGY
What emerges from this comparative survey is not a coherent global legal order but a mosaic of regulatory philosophies, each reflecting distinct historical, cultural, and political contingency. The prohibitionist paradigm, rooted in mid-twentieth century international consensus, is visibly fracturing yet it has not been replaced by any unified alternative. The law student observing this landscape must resist the temptation of false clarity: cannabis is simultaneously legal and illegal, tolerated and prosecuted, medically endorsed and criminally proscribed often within the same geopolitical space. As jurisdictions continue to experiment with legalisation, decriminalisation, and medical access, the task of legal scholarship is to furnish the analytical frameworks capable of evaluating these regimes against the principles of proportionality, human rights, and rational governance that underpin the rule of law itself.
Author(s) Name: Anusha Hiremath (KLE LAW College, Bengaluru)
References:
[1] Single Convention on Narcotic Drugs (adopted 30 March 1961, entered into force 13 December 1964) 520 UNTS 151.
[2] ibid art 36.
[3] Convention on Psychotropic Substances (adopted 21 February 1971, entered into force 16 August 1976) 1019 UNTS 175.
[4] United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (adopted 20 December 1988, entered into force 11 November 1990) 1582 UNTS 95.
[5] Controlled Substances Act 1970 (US) 21 USC § 801.
[6] Gonzales v Raich 545 US 1 (2005).
[7] Control, Regulate and Tax Adult Use of Marijuana Act 2016 (California, Proposition 64) Health and Safety Code § 11362.1.
[8] Misuse of Drugs Act 1971 (UK), sch 2
[9] Advisory Council on the Misuse of Drugs, ‘Cannabis: Classification and Public Health’ (ACMD 2008).
[10] R (on the application of Bayer plc) v Secretary of State for Health [2008] EWCA Civ 1311
[11] Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018, SI 2018/1055.
[12] House of Commons Health and Social Care Committee, ‘Cannabis-based Medicinal Products’ (HC 2018–19, 1232).
[13] Tom Decorte and others, ‘Cannabis Social Clubs in Europe’ (2017) 42 EJCB 255.
[14] Cannabis Act 2018 (Canada) SC 2018, c 16.
[15] Narcotic Drugs and Psychotropic Substances Act 1985 (India) s 2(iii).
[16] State of Punjab v Baldev Singh (1999) 6 SCC 172.